Sectors & IndustriesHealthcareMedical Instruments & Supplies

Best Medical Stocks to Buy Now (2025)

Top medical stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best medical stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best medical stocks to buy right now are:

Infusystem Holdings (NYSEMKT:INFU) is the #1 top medical stock out of 55 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Infusystem Holdings (NYSEMKT:INFU) is: Value: C, Growth: B, Momentum: D, Sentiment: C, Safety: C, Financials: B, and AI: C.

Infusystem Holdings (NYSEMKT:INFU) has a Due Diligence Score of 28, which is equal to the medical industry average of 28.

INFU passed 8 out of 33 due diligence checks and has average fundamentals. Infusystem Holdings has seen its stock lose -16.84% over the past year, overperforming other medical stocks by 23 percentage points.

Embecta (NASDAQ:EMBC) is the #2 top medical stock out of 55 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Embecta (NASDAQ:EMBC) is: Value: A, Growth: C, Momentum: C, Sentiment: B, Safety: D, Financials: B, and AI: B.

Embecta (NASDAQ:EMBC) has a Due Diligence Score of 31, which is 3 points higher than the medical industry average of 28.

EMBC passed 11 out of 38 due diligence checks and has average fundamentals. Embecta has seen its stock lose -20.62% over the past year, overperforming other medical stocks by 19 percentage points.

Embecta has an average 1 year price target of $20.50, an upside of 76.88% from Embecta's current stock price of $11.59.

Embecta stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Embecta, 50% have issued a Strong Buy rating, 0% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Dentsply Sirona (NASDAQ:XRAY) is the #3 top medical stock out of 55 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Dentsply Sirona (NASDAQ:XRAY) is: Value: B, Growth: C, Momentum: D, Sentiment: A, Safety: B, Financials: C, and AI: C.

Dentsply Sirona (NASDAQ:XRAY) has a Due Diligence Score of 28, which is equal to the medical industry average of 28.

XRAY passed 9 out of 38 due diligence checks and has average fundamentals. Dentsply Sirona has seen its stock lose -41.5% over the past year, underperforming other medical stocks by -1 percentage points.

Dentsply Sirona has an average 1 year price target of $20.50, an upside of 24.62% from Dentsply Sirona's current stock price of $16.45.

Dentsply Sirona stock has a consensus Buy recommendation according to Wall Street analysts. Of the 10 analysts covering Dentsply Sirona, 20% have issued a Strong Buy rating, 20% have issued a Buy, 60% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 9 medical stocks that have issued dividends in the past year, the 3 medical stocks with the highest dividend yields are:

Dentsply Sirona (NASDAQ:XRAY) has an annual dividend yield of 2.92%, which is 1 percentage points higher than the medical industry average of 1.52%. Dentsply Sirona's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Dentsply Sirona's dividend has shown consistent growth over the last 10 years.

Dentsply Sirona's dividend payout ratio of -14.2% indicates that its dividend yield might not be sustainable for the long-term.

Embecta (NASDAQ:EMBC) has an annual dividend yield of 2.59%, which is 1 percentage points higher than the medical industry average of 1.52%.

Embecta's dividend payout ratio of 66.7% indicates that its dividend yield is sustainable for the long-term.

Becton Dickinson & Co (NYSE:BDX) has an annual dividend yield of 2.33%, which is 1 percentage points higher than the medical industry average of 1.52%. Becton Dickinson & Co's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Becton Dickinson & Co's dividend has shown consistent growth over the last 10 years.

Becton Dickinson & Co's dividend payout ratio of 76.8% indicates that its dividend yield is sustainable for the long-term.

Medical stocks were down -1.8% in the last day, and up 1.77% over the last week. Alcon was the among the top losers in the medical instruments & supplies industry, dropping -6.45% yesterday.

Alcon shares are trading lower after the company reported worse-than-expected Q1 financial results and cut its FY25 adjusted EPS guidance below estimates.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued medical stocks right now are:

Embecta (NASDAQ:EMBC) is the most undervalued medical stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Embecta has a valuation score of 57, which is 39 points higher than the medical industry average of 18. It passed 4 out of 7 valuation due diligence checks.

Embecta's stock has dropped -20.62% in the past year. It has overperformed other stocks in the medical industry by 19 percentage points.

Teleflex (NYSE:TFX) is the second most undervalued medical stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Teleflex has a valuation score of 43, which is 25 points higher than the medical industry average of 18. It passed 3 out of 7 valuation due diligence checks.

Teleflex's stock has dropped -41.09% in the past year. It has underperformed other stocks in the medical industry by -1 percentage points.

Hologic (NASDAQ:HOLX) is the third most undervalued medical stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Hologic has a valuation score of 57, which is 39 points higher than the medical industry average of 18. It passed 4 out of 7 valuation due diligence checks.

Hologic's stock has dropped -26.82% in the past year. It has overperformed other stocks in the medical industry by 13 percentage points.

47.37% of medical stocks rated by analysts are a strong buy right now. On average, analysts expect medical stocks to rise by 27.45% over the next year.

0% of medical stocks have a Zen Rating of A (Strong Buy), 23.81% of medical stocks are rated B (Buy), 52.38% are rated C (Hold), 14.29% are rated D (Sell), and 9.52% are rated F (Strong Sell).